These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6627828)

  • 1. Influence of uremia, hemodialysis, and nonesterified fatty acids on zomepirac plasma protein binding.
    Pritchard JF; O'Neill PJ; Affrime MB; Lowenthal DT
    Clin Pharmacol Ther; 1983 Nov; 34(5):681-8. PubMed ID: 6627828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of uremia and hemodialysis on the plasma protein binding of tolmetin.
    Pritchard JF; O'Neill PJ; Affrime MB; Lowenthal DT
    Pharmacology; 1984; 29(6):312-9. PubMed ID: 6505005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of zomepirac sodium in man.
    O'Neill PJ; Yorgey KA; Renzi NL; Williams RL; Benet LZ
    J Clin Pharmacol; 1982 Oct; 22(10):470-6. PubMed ID: 7174855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irreversible binding of zomepirac to plasma protein in vitro and in vivo.
    Smith PC; McDonagh AF; Benet LZ
    J Clin Invest; 1986 Mar; 77(3):934-9. PubMed ID: 3949982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac.
    Smith PC; Langendijk PN; Bosso JA; Benet LZ
    Clin Pharmacol Ther; 1985 Aug; 38(2):121-7. PubMed ID: 3874742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes.
    Etinger A; Kumar SR; Ackley W; Soiefer L; Chun J; Singh P; Grossman E; Matalon A; Holzman RS; Meijers B; Lowenstein J
    PLoS One; 2018; 13(2):e0192770. PubMed ID: 29470534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent pharmacokinetics and renal handling of zomepirac in rhesus monkeys.
    O'Neill PJ; Yorgey KA; McKown LA
    J Pharmacol Exp Ther; 1981 Dec; 219(3):665-8. PubMed ID: 7299689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism.
    Smith PC; Benet LZ; McDonagh AF
    Drug Metab Dispos; 1990; 18(5):639-44. PubMed ID: 1981713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the pharmacokinetics and metabolism of zomepirac in man and animals.
    Muschek LD; Grindel JM
    J Clin Pharmacol; 1980 Apr; 20(4):223-9. PubMed ID: 6769977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zomepirac kinetics in healthy males.
    Nayak RK; Ng KT; Gottlieb S; Plostnieks J
    Clin Pharmacol Ther; 1980 Mar; 27(3):395-401. PubMed ID: 7357796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal handling of zomepirac sodium (McN-2783-21-98) in the rat.
    O'Neill PJ; Yorgey KA; Migdalof BH; Gussin RZ
    J Pharmacol Exp Ther; 1979 Jun; 209(3):366-70. PubMed ID: 35605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zomepirac--aspirin interactions in man.
    Desiraju RK; Nayak RK; Pritchard JF
    J Clin Pharmacol; 1984; 24(8-9):371-80. PubMed ID: 6480878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma.
    Ojingwa JC; Spahn-Langguth H; Benet LZ
    J Pharmacokinet Biopharm; 1994 Feb; 22(1):19-40. PubMed ID: 8027947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal glucuronidation of zomepirac in patients with cirrhosis of the liver.
    Witassek F; Bircher J; Huguenin P; Preisig R
    Hepatology; 1983; 3(3):415-22. PubMed ID: 6840687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of nonesterified fatty acids and lysolecithins on thyroxine binding to thyroxine-binding globulin and transthyretin.
    Lim CF; Munro SL; Wynne KN; Topliss DJ; Stockigt JR
    Thyroid; 1995 Aug; 5(4):319-24. PubMed ID: 7488876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodialysis and red cell cation transport in uremia: role of membrane free fatty acids.
    Kelly RA; Canessa ML; Steinman TI; Mitch WE
    Kidney Int; 1989 Feb; 35(2):595-603. PubMed ID: 2540372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of the plasma protein binding of theophylline in health.
    Buss D; Leopold D; Smith AP; Routledge PA
    Br J Clin Pharmacol; 1983 Apr; 15(4):399-405. PubMed ID: 6849774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diminished protein binding capacity of uremic sera for valproate following hemodialysis: role of free fatty acids and uremic compounds.
    Dasgupta A; Jacques M; Malhotra D
    Am J Nephrol; 1996; 16(4):327-33. PubMed ID: 8739287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of development, aging, and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and alpha 1-acid glycoprotein: implications for binding of drugs.
    Pacifici GM; Viani A; Taddeucci-Brunelli G; Rizzo G; Carrai M; Schulz HU
    Ther Drug Monit; 1986; 8(3):259-63. PubMed ID: 3750366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma protein binding of zomepirac sodium.
    O'Neill PJ
    J Pharm Sci; 1981 Jul; 70(7):818-9. PubMed ID: 7264940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.